comparemela.com

Latest Breaking News On - குறி ப்ளாஸ்க்கோவிச் - Page 1 : comparemela.com

Can CBD Be the Next Superbug Slayer?

The syringe was very full, very large, and it would make sitting down uncomfortable for a while. Kit had gone to the health center in Chicago for a full panel of STI tests it had been a minute, after all, and regular screenings are an important part of safe, multi-partner relationships. During the test, they were told the health center would be double-checking for gonorrhea there s a new antibiotic-resistant strain about, Kit explains. Kit tested positive for the bacteria. Fearing the chance it was the superbug version one resistant to antibiotics the staff shot Kit up with a double dose of antibiotics (in that very full, very large syringe) and left them with a stern warning to avoid all sexual activity, lest they potentially infect someone else.

Medicinal cannabis: ′Wonder drug′ or work in progress? | Science| In-depth reporting on science and technology | DW

Spectrum: New Peers Review takes on neurodegeneration CBD is less psychoactive than THC. In fact, CBD may even reduce the psychoactive elements in THC. CBD has antidepressant and anti-inflammatory characteristics.  Cannabidiol is not to be mistaken for cannabinol (CBN). CBN was the first cannabinoid to be detected. As with CBD, CBN has anti-inflammatory properties. Binding to the body Cannabinoids also exist naturally in our bodies. They are called endocannabinoids and are part of the endocannabinoid system, which allows phytocannabinoids, those derived from plants, to affect us. THC, for instance, binds to CB1 cannabinoid receptors in the brain, and that starts a process that releases its psychoactive effect.

Stewardship / Resistance Scan for Feb 23, 2021

CARB-X to fund development of drug to rejuvenate ineffective antibiotics CARB-X announced today that it is awarding up to $2.2 million to the University of Queensland s Institute for Molecular Bioscience (IMB) to continue developing new compounds designed to boost antibiotics that have become ineffective against drug-resistant bacterial infections. The award will help fund IMB s octapeptins research program, which is developing octapeptin peptides that can disrupt the protective outer cell membrane of drug-resistant gram-negative bacteria, allowing antibiotics that have lost efficacy to work again. IMB researchers are currently trying to identify which antibiotics octapeptins are best at helping and can be combined with.

X-factor to help antibiotics regain their spark

Share Holding off the rise of superbugs could be achieved by ‘resuscitating’ old antibiotics, with The University of Queensland researchers leading an international project to help combat the growing threat. CARB-X, a global non-profit partnership funding the world’s largest antibacterial development pipeline, has funded the $AU2.9m project at UQ’s Institute for Molecular Bioscience (IMB). Associate Professor Mark Blaskovich, Dr Alysha Elliott and Dr Johannes Zuegg will assess which antibiotics that are losing their effectiveness could be revived by combining them with a compound from a new family of antibiotics. “We are running out of time to outsmart the most dangerous drug-resistant bacteria, the sort of infections that can cause deadly bacterial sepsis, pneumonia, urinary tract and wound infections,” Dr Blaskovich said.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.